At #AACR26: #ChaeLab @NUFeinbergMed presents the first real-world analysis evaluating survival outcomes using a methylation-based ctDNA assay (@GuardantHealth Reveal) in definitively treated NSCLC! 🫁✨

Key findings from the 78-patient cohort (median follow-up 22.3 mo):
🚨 Early Warning: ctDNA detection preceded radiographic recurrence in 10/11 cases (~91%).
📉 Predictive Value (HR):
• 6-mo RFS: HR 4.35 (p=0.017)
• Any-time RFS: HR 5.20 (p<0.01)

This study reinforces the power of #liquidbiopsy for personalized post-treatment surveillance. 🔬📊
@OncoAlert @oncodaily @LurieCancer @NM_Lung @NorthwesternMed @AACR